Announcements
- MeiraGTx to Participate in Upcoming Investor Conferences
- MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
- MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
- MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
- MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
- MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
- MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
- MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
- MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
- MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
More ▼
Key statistics
As of last trade, MeiraGTx Holdings PLC (328:FRA) traded at 4.56, 39.88% above the 52 week low of 3.26 set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.56 |
---|---|
High | 4.56 |
Low | 4.56 |
Bid | 4.56 |
Offer | 4.76 |
Previous close | 4.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 64.31m |
Free float | 41.84m |
P/E (TTM) | -- |
Market cap | 320.89m USD |
EPS (TTM) | -1.58 USD |
Data delayed at least 15 minutes, as of May 02 2024 07:12 BST.
More ▼